Active, not recruitingPhase 1NCT05646082

Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART) Refractory HIV Associated Kaposi Sarcoma

Studying Kaposi sarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Imperial College London
Intervention
Dostarlimab in Combination Antiretroviral Therapy(drug)
Enrollment
15 target
Eligibility
18 years · All sexes
Timeline
2023 – 2026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05646082 on ClinicalTrials.gov

Other trials for Kaposi sarcoma

Additional recruiting or active studies for the same condition.

See all trials for Kaposi sarcoma →

← Back to all trials